Takeda sheds US rights to azilsartan products
This article was originally published in Scrip
Executive Summary
Arbor Pharmaceuticals is to take over US sales and marketing activities for Takeda's azilsartan medoxomil-containing antihypertensive products, with the Japanese firm saying that it wants to focus commercial resources in this market on other recent and upcoming launches.